CyBio AG has delivered a robotics system to Boehringer Ingelheim for replicating plates for its compound management activities in its Biberach location as part of a major contract. For the company, a subsidiary of Analytik Jena, the contract comprised delivery of the complete solution inclu ... more
Boehringer Ingelheim to acquire STEAG microParts GmbH
Boehringer Ingelheim is to acquire the microtechnology specialist STEAG microParts GmbH from STEAG AG, Essen, Germany. STEAG microParts, established in 1990, is a worldwide leader in microsystem technology with headquarters at the hub of technology in Dortmund, Germany.
STEAG microParts' core product is the innovative Respimat® Soft MistTM Inhaler which was co-developed together with Boehringer Ingelheim. This novel medicinal inhaler, which generates a slow-moving long-lasting soft mist through purely mechanical means, allows for excellent penetration of the lungs. Respimat® Soft MistTM Inhaler offers all patients with asthma or COPD (chronic-obstructive airways disease) effective medication in precise doses.
"The acquisition of STEAG microParts fits very well into our production strategy," explained Dr Hans-Jürgen Leuchs, responsible within the Boehringer Ingelheim Board of Managing Directors for production and technology. "We see Respimat® Soft MistTM Inhaler as the inhalation device of the future; it is to be tested in clinical studies successively with different respiratory products. We thank STEAG microParts for the excellent cooperation in recent years and now look forward to having full control of the entire production chain following the acquisition. In addition, the expertise in development and production at STEAG microParts, especially in microsystem technology, will be an excellent supplement to our development activities in the field of innovative Drug Delivery".
- STEAG microParts
- Boehringer Ingelheim
- clinical trials
BioTrove, Inc. announced its RapidFire® High-Throughput Mass Spectrometry (RF-MS) screening platform was installed in its first European customer site at Boehringer Ingelheim in Biberach, Germany. The RapidFire system, which is being used for expanded in vitro ADME applications at Boehringe ... more
Cenix BioScience GmbH announced that it has signed a research agreement to support Boehringer Ingelheim in its ongoing efforts to discover novel therapeutic drug targets. Cenix will apply its expertise in combining high throughput (HT) applications of RNAi-based gene silencing with high co ... more